Natera has introduced a non-invasive prenatal test (NIPT), Fetal Focus, specifically designed for inherited conditions. According to the company, when a pregnant individual is found to carry a ...

A $9.5M settlement resolves a lawsuit that alleged Natera failed to clearly inform patients of potential out-of-pocket costs ...

Natera Inc. (NASDAQ: NTRA) announced the launch of Fetal Focus, a noninvasive prenatal test for inherited conditions that analyzes fetal DNA from a mother's blood sample. The test addresses situations ...

OAKLAND, Calif. (CN) — A federal judge approved Thursday a final settlement to a class of consumers who used a prenatal test that could produce a high percentage of false positives for rare genetic ...

Natera’s updated analyst models now point to a higher Fair Value price target of US$344.33, up from US$282.14, which is roughly a 22% change in the modeled outcome. Analysts are tying this shift to ...

Natera (NTRA) is back in focus after the US Food and Drug Administration granted Breakthrough Device designation to its multi ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing and precision medicine, today announced the launch of Fetal Focus, a noninvasive prenatal ...